Annette Wundes
University of Washington
HaematopoiesisInternal medicineSurgeryOncologyAntibodyAdverse effectProgenitor cellImmunologyClinical endpointVideoconferencingDimethyl fumarateHematopoietic stem cell transplantationTolerabilityDiseaseImmunosuppressionMultiple sclerosisProgressive multifocal leukoencephalopathyNatalizumabTransplantationFamily medicineMedicineGastroenterology
39Publications
12H-index
600Citations
Publications 40
Newest
#1Paul Kamudoni (MSD: Merck & Co.)
#1Paul Kamudoni (Merck KGaA)H-Index: 3
Last. Kevin N. Alschuler (UW: University of Washington)H-Index: 21
view all 13 authors...
Abstract null null Background null Fatigue is one of the most common and the single most disabling symptom of multiple sclerosis (MS). However, there is a lack of consensus on the most appropriate fatigue measures in clinical practice and research, based upon rigorously validated, generalizable, and publicly available instruments. The objective of this research was to generate additional evidence regarding the validity and applicability of the PROMIS SF v1.0 – Fatigue (MS) 8a, including content ...
Source
#1Neda Zarghami Esfanhani (KP: Kaiser Permanente)
#2Annette Wundes (KP: Kaiser Permanente)
Last. Scott D. Newsome (Johns Hopkins University)H-Index: 27
view all 10 authors...
A 31-year-old woman presented with fever, ataxia, double vision, confusion, and auditory hallucinations, preceded by 2 weeks of cough, increased oral secretions, and dermatomal rash. Her medical history was unremarkable. Her family history was notable for first-degree relatives with autoimmune
1 CitationsSource
#1Annette Wundes (University of Washington Medical Center)H-Index: 12
#2Sibyl WrayH-Index: 7
Last. Robert T. Naismith (WashU: Washington University in St. Louis)H-Index: 31
view all 13 authors...
Background:Diroximel fumarate (DRF) is a novel oral fumarate approved for relapsing forms of multiple sclerosis (MS). DRF demonstrated significantly improved gastrointestinal (GI) tolerability vers...
2 CitationsSource
Background: Natalizumab is an approved treatment for relapsing-remitting multiple sclerosis (RRMS) since 2006. Though infusion reactions are usually mild, occur typically within the first six months of treatment and clinically relevant infusion reactions are extraordinarily rare, there is a mandatory one-hour post-infusion monitoring after each dose, independent of treatment duration. This has posed concerns of unnecessarily increasing SARS-CoV2 exposure risks for patients and staff. Objectives:...
Source
#1Robert T. Naismith (WashU: Washington University in St. Louis)H-Index: 9
#2Jerry S. Wolinsky (University of Texas Health Science Center at Houston)H-Index: 77
Last. Richard Leigh-Pemberton (Alkermes)H-Index: 5
view all 20 authors...
Background:Diroximel fumarate (DRF) is a novel oral fumarate for patients with relapsing–remitting multiple sclerosis (RRMS). DRF and the approved drug dimethyl fumarate yield bioequivalent exposur...
16 CitationsSource
Abstract Teriflunomide is an oral disease modifying therapy for relapsing-remitting multiple sclerosis (RRMS). Gastrointestinal (GI) side effects occurred in 15-17.9% of patients in the clinical trials and usually were mild and self-limiting. Few cases of inflammatory colitis related to teriflunomide and leflunomide, a prodrug which converts to teriflunomide and is used in the treatment of rheumatoid arthritis, have been reported but no clinical data is available except for a single case of lymp...
Source
#1Kevin N. Alschuler (UW: University of Washington)H-Index: 21
#2Gloria von Geldern (UW: University of Washington)H-Index: 13
Last. Annette Wundes (UW: University of Washington)H-Index: 12
view all 7 authors...
Abstract Background: Healthcare providers caring for people with multiple sclerosis (MS) have had significant concerns about the intersection of MS and COVID-19. As a result, there has been an urgency to understand and share information about how to best provide MS clinical care during COVID-19. The Project ECHO model is well-suited for this challenge, as it provides a uniquely efficient and effective approach to sharing information in real-time using real cases. We report on the translation of ...
Source
#1James D. Bowen (UW: University of Washington)H-Index: 63
#2Justine Brink (UW: University of Washington)H-Index: 1
Last. Pavle Repovic (UW: University of Washington)H-Index: 8
view all 7 authors...
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is marked by a wide range and severity of symptoms. Most patients have mild to moderate symptoms, whereas 10%–15% require hospitalization. Mortality is higher with cardiovascular disorders, diabetes, and older age.1
23 CitationsSource
#1Annette Wundes (University of Washington Medical Center)H-Index: 12
#2Jerry S. Wolinsky (University of Texas Health Science Center at Houston)H-Index: 77
Last. Robert T. Naismith (WashU: Washington University in St. Louis)H-Index: 31
view all 13 authors...
Objective: To evaluate tolerability and impact of gastrointestinal (GI) adverse events (AEs) with diroximel fumarate (DRF) versus dimethyl fumarate (DMF) in patients with relapsing-remitting multiple sclerosis (MS). Background: DRF is an investigational, oral fumarate for relapsing forms of MS with an improved GI tolerability profile compared to DMF. DRF 462 mg and DMF 240 mg produce bioequivalent exposure of the active metabolite monomethyl fumarate. Well-tolerated treatment options may lower t...
#1Dawn M. EhdeH-Index: 2
view all 12 authors...
Source